Overall treatment outcome of patients treated with first-line imatinib interim therapy (n = 29)
. | . | . | . | . | . | Response to imatinib* . | . | . | . | . | GVHD (grade) . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Age, y/sex . | BCR-ABL isoform . | Karyotype . | Status before imatinib . | Imatinib dose, mg/d . | After first imatinib . | After second imatinib . | Pre-SCT status . | Graft source . | Time to SCT, d . | Acute . | Chronic . | Current DFS status; cause of death . | ||
| 1 | 39/F | p190 | Additional | CR | 600 | CR (-0.20) | Mol CR (UD) | Mol CR | MSD/BM | 128 | + (II) | + (E) | Died 32 mo; NRM | ||
| 2 | 29/M | p210 | Additional | CR | 400 | CR (-0.89) | CR (-0.27) | CR | MSD/BM | 136 | - | - | Alive 45 + mo | ||
| 3 | 40/M | p210 | Additional | CR | 600 | CR (-0.40) | CR (-0.79) | CR | MSD/BM | 132 | - | + (L) | Alive 43 + mo | ||
| 4 | 39/F | p190 | Additional | CR | 400 | CR (-0.35) | Mol CR (UD) | Mol CR | MSD/BM | 127 | - | - | Alive 42 + mo | ||
| 5 | 26/M | p190 | Ph alone | CR | 400 | CR (-1.22) | CR (-0.31) | CR | MSD/BM | 134 | - | - | Alive 39 + mo | ||
| 6 | 20/M | p210 | Additional | CR | 600 | CR (-0.97) | CR (-0.08) | CR | MSD/BM | 158 | - | + (L) | Alive 37 + mo | ||
| 7 | 43/F | p210 | Additional | CR | 600 | CR (-1.85) | CR (-0.09) | CR | MSD/BM | 139 | + (III) | NA | Died 3 mo; NRM | ||
| 8 | 40/F | p190 | Ph alone | CR | 600 | CR (-0.50) | CR (-1.09) | CR | MSD/BM | 126 | - | + (L) | Alive 34 + mo | ||
| 9 | 31/M | p210 | Ph alone | CR | 400 | CR (-0.93) | CR (-0.11) | CR | MSD/BM | 120 | - | - | Alive 32 + mo | ||
| 10 | 27/M | p190 | Additional | CR | 600 | Relapse (+0.93) | Relapse (+1.63) | Relapse | NA | NA | NA | NA | Died before SCT | ||
| 11 | 38/F | p190 | Additional | CR | 400 | CR (-0.20) | CR (-0.07) | CR | MSD/BM | 141 | + (II) | + (E) | Alive 29 + mo | ||
| 12 | 39/M | p210 | Ph alone | Refractory | 600 | CR (-0.89) | NA | CR | MSD/BM | 126 | - | + (L) | Alive 28 + mo | ||
| 13 | 30/M | p190 | Additional | CR | 400 | CR (-1.48) | NA | CR | MSD/BM | 56 | - | - | Alive 27 + mo | ||
| 14 | 44/M | p190 | Additional | Refractory | 600 | Refractory (+0.54) | NA | Refractory | MSD/PB | 137 | + (IV) | NA | Died 4 mo; NRM | ||
| 15 | 18/M | p190 | Additional | CR | 400 | CR (-0.48) | Mol CR (UD) | Mol CR | MSD/BM | 151 | - | + (E) | Alive 26 + mo | ||
| 16 | 31/M | p190 | Ph alone | Refractory | 600 | CR (-0.76) | CR (-1.31) | CR | MUD/BM | 191 | - | - | Died 9 mo; relapse | ||
| 17 | 55/F | p210 | Ph alone | CR | 600 | CR (-0.77) | Mol CR (UD) | Mol CR | MSD/BM | 126 | - | + (L) | Alive 25 + mo | ||
| 18 | 21/F | p210 | Ph alone | CR | 600 | CR (-0.48) | CR (-0.81) | CR | MSD/BM | 141 | + (II) | - | Alive 24 + mo | ||
| 19 | 28/F | p190 | Additional | Refractory | 600 | CR (-0.60) | CR (-1.02) | CR | MSD/BM | 151 | - | - | Alive 22 + mo | ||
| 20 | 36/F | p210 | Ph alone | CR | 400 | CR (-1.13) | CR (-0.56) | CR | MUD/BM | 217 | + (III) | + (L) | Alive 20 + mo | ||
| 21 | 23/F | p190 | Additional | CR | 400 | CR (-0.44) | CR (-0.16) | CR | MUD/BM | 176 | - | - | Alive 19 + mo | ||
| 22 | 40/F | p190 | Additional | CR | 400 | CR (-0.39) | Mol CR (UD) | Mol CR | MSD/BM | 162 | - | - | Alive 19 + mo | ||
| 23 | 48/F | p210 | Ph alone | CR | 600 | CR (-0.89) | CR (-0.31) | CR | MSD/BM | 215 | + (II) | - | Alive 18 + mo | ||
| 24 | 44/F | p190 | Ph alone | Refractory | 600 | Refractory (+1.10) | Refractory (+0.90) | Refractory | MUD/PB | 171 | + (II) | + (L) | Alive 18 + mo | ||
| 25 | 35/F | p190 | Ph alone | CR | 400 | CR (-0.89) | CR (-0.37) | CR | MSD/BM | 135 | - | - | Alive 17 + mo | ||
| 26 | 20/M | p190 | Additional | Refractory | 600 | Refractory (+0.67) | NA | Refractory | MSD/PB | 101 | + (II) | + (L) | Alive 16 + mo | ||
| 27 | 28/M | p210 | Ph alone | CR | 600 | CR (-1.23) | Mol CR (UD) | Mol CR | MUD/BM | 176 | - | + (L) | Alive 15 + mo | ||
| 28 | 37/M | p210 | Additional | CR | 400 | CR (-0.70) | CR (-0.62) | CR | MUD/BM | 181 | + (II) | - | Alive 14 + mo | ||
| 29 | 52/F | p210 | Ph alone | CR | 400 | CR (-1.26) | Mol CR (UD) | Mol CR | MSD/PB | 129 | - | - | Alive 12 + mo | ||
. | . | . | . | . | . | Response to imatinib* . | . | . | . | . | GVHD (grade) . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Age, y/sex . | BCR-ABL isoform . | Karyotype . | Status before imatinib . | Imatinib dose, mg/d . | After first imatinib . | After second imatinib . | Pre-SCT status . | Graft source . | Time to SCT, d . | Acute . | Chronic . | Current DFS status; cause of death . | ||
| 1 | 39/F | p190 | Additional | CR | 600 | CR (-0.20) | Mol CR (UD) | Mol CR | MSD/BM | 128 | + (II) | + (E) | Died 32 mo; NRM | ||
| 2 | 29/M | p210 | Additional | CR | 400 | CR (-0.89) | CR (-0.27) | CR | MSD/BM | 136 | - | - | Alive 45 + mo | ||
| 3 | 40/M | p210 | Additional | CR | 600 | CR (-0.40) | CR (-0.79) | CR | MSD/BM | 132 | - | + (L) | Alive 43 + mo | ||
| 4 | 39/F | p190 | Additional | CR | 400 | CR (-0.35) | Mol CR (UD) | Mol CR | MSD/BM | 127 | - | - | Alive 42 + mo | ||
| 5 | 26/M | p190 | Ph alone | CR | 400 | CR (-1.22) | CR (-0.31) | CR | MSD/BM | 134 | - | - | Alive 39 + mo | ||
| 6 | 20/M | p210 | Additional | CR | 600 | CR (-0.97) | CR (-0.08) | CR | MSD/BM | 158 | - | + (L) | Alive 37 + mo | ||
| 7 | 43/F | p210 | Additional | CR | 600 | CR (-1.85) | CR (-0.09) | CR | MSD/BM | 139 | + (III) | NA | Died 3 mo; NRM | ||
| 8 | 40/F | p190 | Ph alone | CR | 600 | CR (-0.50) | CR (-1.09) | CR | MSD/BM | 126 | - | + (L) | Alive 34 + mo | ||
| 9 | 31/M | p210 | Ph alone | CR | 400 | CR (-0.93) | CR (-0.11) | CR | MSD/BM | 120 | - | - | Alive 32 + mo | ||
| 10 | 27/M | p190 | Additional | CR | 600 | Relapse (+0.93) | Relapse (+1.63) | Relapse | NA | NA | NA | NA | Died before SCT | ||
| 11 | 38/F | p190 | Additional | CR | 400 | CR (-0.20) | CR (-0.07) | CR | MSD/BM | 141 | + (II) | + (E) | Alive 29 + mo | ||
| 12 | 39/M | p210 | Ph alone | Refractory | 600 | CR (-0.89) | NA | CR | MSD/BM | 126 | - | + (L) | Alive 28 + mo | ||
| 13 | 30/M | p190 | Additional | CR | 400 | CR (-1.48) | NA | CR | MSD/BM | 56 | - | - | Alive 27 + mo | ||
| 14 | 44/M | p190 | Additional | Refractory | 600 | Refractory (+0.54) | NA | Refractory | MSD/PB | 137 | + (IV) | NA | Died 4 mo; NRM | ||
| 15 | 18/M | p190 | Additional | CR | 400 | CR (-0.48) | Mol CR (UD) | Mol CR | MSD/BM | 151 | - | + (E) | Alive 26 + mo | ||
| 16 | 31/M | p190 | Ph alone | Refractory | 600 | CR (-0.76) | CR (-1.31) | CR | MUD/BM | 191 | - | - | Died 9 mo; relapse | ||
| 17 | 55/F | p210 | Ph alone | CR | 600 | CR (-0.77) | Mol CR (UD) | Mol CR | MSD/BM | 126 | - | + (L) | Alive 25 + mo | ||
| 18 | 21/F | p210 | Ph alone | CR | 600 | CR (-0.48) | CR (-0.81) | CR | MSD/BM | 141 | + (II) | - | Alive 24 + mo | ||
| 19 | 28/F | p190 | Additional | Refractory | 600 | CR (-0.60) | CR (-1.02) | CR | MSD/BM | 151 | - | - | Alive 22 + mo | ||
| 20 | 36/F | p210 | Ph alone | CR | 400 | CR (-1.13) | CR (-0.56) | CR | MUD/BM | 217 | + (III) | + (L) | Alive 20 + mo | ||
| 21 | 23/F | p190 | Additional | CR | 400 | CR (-0.44) | CR (-0.16) | CR | MUD/BM | 176 | - | - | Alive 19 + mo | ||
| 22 | 40/F | p190 | Additional | CR | 400 | CR (-0.39) | Mol CR (UD) | Mol CR | MSD/BM | 162 | - | - | Alive 19 + mo | ||
| 23 | 48/F | p210 | Ph alone | CR | 600 | CR (-0.89) | CR (-0.31) | CR | MSD/BM | 215 | + (II) | - | Alive 18 + mo | ||
| 24 | 44/F | p190 | Ph alone | Refractory | 600 | Refractory (+1.10) | Refractory (+0.90) | Refractory | MUD/PB | 171 | + (II) | + (L) | Alive 18 + mo | ||
| 25 | 35/F | p190 | Ph alone | CR | 400 | CR (-0.89) | CR (-0.37) | CR | MSD/BM | 135 | - | - | Alive 17 + mo | ||
| 26 | 20/M | p190 | Additional | Refractory | 600 | Refractory (+0.67) | NA | Refractory | MSD/PB | 101 | + (II) | + (L) | Alive 16 + mo | ||
| 27 | 28/M | p210 | Ph alone | CR | 600 | CR (-1.23) | Mol CR (UD) | Mol CR | MUD/BM | 176 | - | + (L) | Alive 15 + mo | ||
| 28 | 37/M | p210 | Additional | CR | 400 | CR (-0.70) | CR (-0.62) | CR | MUD/BM | 181 | + (II) | - | Alive 14 + mo | ||
| 29 | 52/F | p210 | Ph alone | CR | 400 | CR (-1.26) | Mol CR (UD) | Mol CR | MSD/PB | 129 | - | - | Alive 12 + mo | ||
GVHD indicates graft-versus-host disease; DFS, disease-free survival; Mol CR, molecular complete remission; UD, undetectable; NA, not available; MSD, matched sibling donor; MUD, matched unrelated donor; BM, bone marrow; PB, peripheral blood; E, extensive; L, limited; mo, months; and NRM, nonrelapse mortality.
Values in parentheses indicate the changes of BCR-ABL/ABL ratio between each paired sample (before and after imatinib level)